IP Library Granted Patent US 10,501,540
Granted Patent B2
US 10,501,540 · App. 15/302,927 · Granted Dec 10, 2019

Immunoglobulins binding human Vγ9 Vδ2 T cell receptors

Inventors: Johannes Jelle Van Der Vliet (Amsterdam, NL); Renée Cornelia Gerarda De Bruin (Amsterdam, NL); Tanja Denise De Gruijl (Amsterdam, NL); Hendrik Marinus Willem Verheul (Amsterdam, NL)
Assignee: LAVA Therapeutics B.V.
C07K16/2809C07K2317/21C07K2317/22C07K2317/565C07K2317/569C07K2317/622C07K2317/70C07K2317/75C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,501,540
App. No.
15/302,927
Granted
Dec 10, 2019
Kind
B2
Abstract

The invention is in the field of medicine and relates to immunology, and relates in particular to human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules. Human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules are in particular for use in medical treatment and/or useful in assays with human Vγ9Vδ2 T cells, wherein human Vγ9Vδ2 T cells may be modulated.

Claims (32)

1. A human Vγ9Vδ2 T cell receptor binding immunoglobulin molecule, comprising a CDR1 region, and a CDR2 region,

and a CDR 3 region, wherein the CDR1, CDR2 and CDR3 regions comprise:

the amino acid sequences set forth in SEQ ID Nos: 4, 5 and 6, respectively, or

the amino acid sequences set forth in SEQ ID Nos: 7, 8 and 9, respectively, or

the amino acid sequences set forth in SEQ ID Nos: 4, 10 and 11, respectively, or

the amino acid sequences set forth in SEQ ID Nos: 12, 13 and 14, respectively, or

the amino acid sequences set forth in SEQ ID Nos: 15, 16 and 17, respectively, or

the amino acid sequences set forth in SEQ ID Nos: 18, 19 and 20, respectively, or

the amino acid sequences set forth in SEQ ID Nos: 18, 21 and 22, respectively, or

the amino acid sequences set forth in SEQ ID Nos: 23, 24 and 25, respectively, or

the amino acid sequences set forth in SEQ ID Nos: 15, 28 and 29, respectively, or

the amino acid sequences set forth in SEQ ID Nos: 31, 32 and 33, respectively, or

the amino acid sequences set forth in SEQ ID Nos: 31, 34 and 35, respectively, or

the amino acid sequences set forth in SEQ ID Nos: 44, 45 and 46, respectively.

2. The immunoglobulin molecule according to claim 1 , wherein the immunoglobulin molecule is a single chain antibody.

3. The immunoglobulin molecule according to claim 1 , wherein the immunoglobulin molecule is a single domain antibody.

4. The immunoglobulin molecule according to claim 1 , comprising one or more of the framework regions selected from the group of amino acid sequences of SEQ ID NOS. 67-70.

5. The immunoglobulin molecule according to claim 1 , wherein the immunoglobulin molecule has an amino acid sequence selected from the group of amino acid sequences consisting of SEQ ID NOS. 48-57, 59, 61, 62 and 66.

6. A nucleotide sequence that encodes an immunoglobulin molecule according to claim 1 .

7. A host cell comprising a nucleotide sequence according to claim 6 .

8. Method for preparing an immunoglobulin molecule according to claim 1 , comprising:

culturing a host cell comprising a nucleotide sequence that encodes the immunoglobulin molecule according to claim 1 ;

allowing the host cell to express the immunoglobulin;

obtaining the immunoglobulin.

9. An immunoglobulin molecule according to claim 1 , wherein the immunoglobulin molecule is an immunoglobulin molecule that activates human Vγ9Vδ2 T cells.

10. The immunoglobulin molecule according to claim 9 , wherein the immunoglobulin molecule is linked to an agent.

11. The immunoglobulin molecule according to claim 1 , which is a bispecific antibody comprising two single domain antibodies, the first single domain antibody comprising the CDR1, CDR2 and CDR3 regions as defined in claim 1 , wherein the first single domain antibody is linked to a second single domain antibody wherein the second single domain antibody binds to a target.

12. The immunoglobulin molecule according to claim 1 , which is a bispecific antibody comprising two single domain antibodies, the first single domain antibody comprising the CDR1, CDR2 and CDR3 regions as defined in claim 1 , wherein the first single domain antibody is linked to a second single domain antibody wherein the second single domain antibody binds to a cancer cell.

13. The immunoglobulin molecule of claim 2 , wherein the single chain antibody is a llama single chain antibody.

14. The immunoglobulin molecule of claim 2 , wherein the single chain antibody is a human single chain antibody.

15. The immunoglobulin molecule of claim 3 , wherein the single domain antibody is a llama single domain antibody.

16. The immunoglobulin molecule of claim 3 , wherein the single domain antibody is a human single domain antibody.

Assignments (4)
CHANGE OF NAME Recorded Feb 10, 2022
From: LAVA THERAPEUTICS B.V.
To: LAVA THERAPEUTICS N.V.
Reel/Frame 059089/0743 →
CHANGE OF NAME Recorded Feb 4, 2022
From: LAVA THERAPEUTICS B.V
To: LAVA THERAPEUTICS N.V.
Reel/Frame 058960/0464 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2017
From: STICHTING VUMC
To: LAVA THERAPEUTICS B.V.
Reel/Frame 044919/0706 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2016
From: VAN DER VLIET, JOHANNES JELLE; DE BRUIN, RENÉE CORNELIA GERARDA; DE GRUIJL, TANJA DENISE; VERHEUL, HENDRIK MARINUS WILLEM
To: STICHTING VUMC
Reel/Frame 040827/0285 →
Priority Claims (1)
NL 2012604 · Apr 10, 2014 · national
Continuity (1)
Related Publication 20170029506A1 · Feb 2, 2017
Cited By (3)
US 12,428,493 US 12,655,218 US 12,673,995